Background: Metformin is one of the most widely prescribed antidiabetic medications with a favorable safety profile. In the last decade, several studies have reported a TSH-lowering effect of metformin in patients with diabetes mellitus. Objective: To review literature data on the role of metformin use on thyroid function tests and the course of thyroid cancer. Methods: We performed a search in the PubMed database using the terms: ‘metformin', ‘thyroid', ‘TSH', ‘diabetes', ‘polycystic ovarian syndrome (PCOS)' and ‘thyroid cancer'. Results: The majority of available evidence suggests that metformin therapy results in a modest reduction of TSH levels in diabetic and/or PCOS patients with thyroid disorder, while thyroid hormone levels remain unaltered. It appears that this effect is independent of thyroid autoimmunity and thyroxine treatment. However, metformin use in subjects with an intact thyroid axis is not associated with a significant change of TSH levels. Concerning thyroid cancer, there is experimental evidence showing antimitogenic properties of metformin in differentiated and medullary thyroid cancer cells. On the other hand, there is also data supporting that metformin administration inhibits iodine uptake by thyroid cells and thus may limit the effectiveness of radioactive iodine treatment. Conclusions: Most studies suggest a TSH suppressive action of metformin in subjects with overt or subclinical thyroid dysfunction, while this is not apparent in euthyroid individuals. It appears that metformin has antimitogenic properties against various thyroid cancer types; however, experimental evidence of reduced efficacy of radioactive iodine treatment following metformin administration may limit its use in the management of differentiated thyroid cancer.

Keywords:
Metformin, Thyroid, Diabetes, TSH, Polycystic ovarian syndrome, Thyroid cancer
1.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
2.
Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ: Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-572.
3.
Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29:759-764.
4.
Diabetes Prevention Program Research Group: Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35:731-737.
5.
Lalau JD, Race JM: Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis'. Diabetes Obes Metab 2001;3:195-201.
6.
Chubb SA, Davis WA, Inman Z, Davis TM: Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. Clin Endocrinol (Oxf) 2005;62:480-486.
7.
Noto H, Goto A, Tsujimoto T, Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411.
8.
Tseng CH: Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol 2012;167:409-416.
9.
Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT: Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012;135:639-646.
10.
Vigersky RA, Filmore-Nassar A, Glass AR: Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006;91:225-227.
11.
Isidro ML, Penín MA, Nemiña R, Cordido F: Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007;32:79-82.
12.
Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, Ovesen L, Jørgensen T: Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019-4024.
13.
Kok P, Roelfsema F, Langendonk JG, Frölich M, Burggraaf J, Meinders AE, Pijl H: High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab 2005;90:4659-4663.
14.
Dall'Asta C, Paganelli M, Morabito A, Vedani P, Barbieri M, Paolisso G, Folli F, Pontiroli AE: Weight loss through gastric banding: effects on TSH and thyroid hormones in obese subjects with normal thyroid function. Obesity (Silver Spring) 2010;18:854-857.
15.
Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, De Martino E, Cimino A, Chiovato L, Agabiti-Rosei E, Castellano M: TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009;32:1589-1590.
16.
Cappelli C, Rotondi M, Pirola I, Agosti B, Formenti A, Zarra E, Valentini U, Leporati P, Chiovato L, Castellano M: Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 2012;167:261-265.
17.
Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R: High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-369.
18.
Rotondi M, Cappelli C, Magri F, Botta R, Dionisio R, Iacobello C, De Cata P, Nappi RE, Castellano M, Chiovato L: Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2011;75:378-381.
19.
Morteza Taghavi S, Rokni H, Fatemi S: Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011;8:47-48.
20.
Krysiak R, Okopien B: Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol (Oxf) 2011;75:404-406.
21.
Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopień B: Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010;62:956-965.
22.
Díez JJ, Iglesias P: Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol (Oxf) 2012, E-pub ahead of print.
23.
Oleandri SE, Maccario M, Rossetto R, Procopio M, Grottoli S, Avogadri E, Gauna C, Ganzaroli C, Ghigo E: Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. J Endocrinol Invest 1999;22:134-140.
24.
Díez JJ, Iglesias P: An analysis of the relative risk for hypothyroidism in patients with type 2 diabetes. Diabet Med 2012;29:1510-1514.
25.
Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP: Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007;148:507-511.
26.
López M, Varela L, Vázquez MJ, Rodríguez-Cuenca S, González CR, Velagapudi VR, Morgan DA, Schoenmakers E, Agassandian K, Lage R, Martínez de Morentin PB, Tovar S, Nogueiras R, Carling D, Lelliott C, Gallego R, Oresic M, Chatterjee K, Saha AK, Rahmouni K, Diéguez C, Vidal-Puig A: Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010;16:1001-1008.
27.
Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A: Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005;184:233-239.
28.
Alevizaki M: Metformin and the thyroid: some questions still remain. Clin Endocrinol (Oxf) 2012, E-pub ahead of print.
29.
Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S: Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 2012, E-pub ahead of print.
30.
Pollak MN: Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778-790.
31.
Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B: Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-2369.
32.
Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC: Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 2011;71:5754-5764.
33.
Hardie DG, Ross FA, Hawley SA: AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-262.
34.
Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H: Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2011;9:69-75.
35.
Chen G, Xu S, Renko K, Derwahl M: Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012;97:E510-E520.
36.
Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L, Vasko V: Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer 2012;19:447-456.
37.
Andrade BM, Araujo RL, Perry RL, Souza EC, Cazarin JM, Carvalho DP, Ceddia RB: A novel role for AMP-kinase in the regulation of the Na+/I- symporter and iodide uptake in the rat thyroid gland. Am J Physiol Cell Physiol 2011;300:C1291-C1297.
38.
Abdulrahman RM, Sips HCM, Smit JWA, Hovens GCJ: Regulation of the NIS promoter by AMPK modulation. Eur Thyroid J 2012;1(suppl 1):165.
39.
Hovens GCJ, Abdulrahman R, Sips H, Smit JWA: Effects of metformin on thyroid function. Eur Thyroid J 2012;1(suppl 1):166.
40.
Andrade BM, Cazarin J, Zancan P, Carvalho DP: AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. Thyroid 2012;22:1063-1068.
© 2013 European Thyroid Association
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.